Mycophenolic acid dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Mycophenolic acid is a transplant drug that damps down the immune system. It was tested on the idea that rapamycin might help mice live longer by damping down the immune system too. It did not extend mouse lifespan in either sex. That points to rapamycin working some other way.
Evidence grade for Mycophenolic acid: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 227 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 227
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved as mycophenolate mofetil and mycophenolate sodium to stop the body rejecting a transplanted organ. It carries boxed warnings, the FDA's strongest, for harm to an unborn baby, cancer and serious infection. No ageing use.
5 effects reported, 4 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Ageing and longevity
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Mycophenolic acid is a transplant drug. It damps down the immune system so a new organ is not rejected. It was tested in mice to learn why rapamycin works.
What people take it for
- Stopping organ transplant rejection, its real use.
- Lupus kidney disease and other immune diseases.
- Nobody sensible takes it for ageing. It was tested to see if a quieter immune system explains rapamycin.
What studies in people showed
In 227 people with lupus kidney disease, it kept the disease quiet better than an older drug. Treatment failed in 16.4 percent against 32.4 percent. In 423 people after a kidney transplant, two forms of it stopped rejection equally well. Nobody has tested it for ageing. Now mice. It did not make either sex live longer.
What people report
Reports, not study results
The good
- In lupus kidney disease, fewer serious side effects than the older drug (23.5 against 33.3 percent).
The bad
- A higher risk of lymphoma and other cancers.
- Serious infections, including a rare brain infection.
- Harm to unborn babies.
- Gut problems and low blood counts.
Where these come from: The harms are from the drug warnings and the trials on this page. We have no user reports.
My bottom line
This drug exists to shut down part of your immune system. It did nothing for mouse lifespan. Nobody should take it for ageing.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. This is an approved medicine. So the missing study in people is for this use, not for the drug. Drug makers paid to test it for what it is approved for. The record on this one is set out below.
- Living longer1 animal or lab study
35 of the 36 indexed goals have no study of any kind behind Mycophenolic acid
No study in people, animals or cells on this page reports a result for these. That does not prove Mycophenolic acid does nothing for them. It does mean anything you have heard about Mycophenolic acid and one of these did not come from a study cited here.
Show full evidence
What is Mycophenolic acid?
Mycophenolic acid is a transplant drug that damps down the immune system. It was tested on the idea that rapamycin might help mice live longer by damping down the immune system too. It did not extend mouse lifespan in either sex. That points to rapamycin working some other way.
Rapamycin is the most reliable drug known for making mice live longer. It is also used to damp down the immune system so transplanted organs are not rejected. That raises an obvious question. Does the longer life come from a quieter immune system, or from blocking mTOR, a growth switch?
Mycophenolic acid is a way to ask. It strongly damps down the immune system, and it works nowhere near mTOR. It blocks the making of DNA building blocks in white blood cells called lymphocytes. If a quieter immune system were doing the work, it should copy at least part of rapamycin's effect.
In the mouse lifespan program's 2024 run, it did not make either sex live longer. That is a useful no. It makes the immune explanation for rapamycin less likely, and leaves blocking mTOR standing.
How does Mycophenolic acid work?
Mycophenolic acid blocks an enzyme (IMPDH) that cells need to build guanine, one of the DNA building blocks, from scratch. T and B lymphocytes rely on building it from scratch, because they are poor at recycling it. So blocking the enzyme stops them multiplying, while mostly sparing other cells. That is why it works in transplants. It is also why it makes a clean test: it damps down immunity without touching the nutrient-sensing switches rapamycin acts on.
What have studies in people found about Mycophenolic acid?
A large record as an approved drug in transplants and autoimmune disease, with serious known harms. Nothing on ageing.
- After kidney transplant, 423 people got one of two forms of the drug for a year, plus cyclosporine and steroids. Both forms prevented rejection about equally well (22.5 and 24.3 percent had a rejection proven by biopsy).
- In lupus kidney disease, 227 people in remission took it or an older drug, azathioprine, for three years. Treatment failed in 16.4 percent against 32.4 percent. Serious side effects were 23.5 against 33.3 percent.
- A standard part of drug combos used to prevent organ transplant rejection.
- Widely used in lupus kidney disease and other autoimmune conditions.
- Boxed warnings, the FDA's strongest, cover harm to unborn babies, a higher risk of lymphoma and other cancers, and serious infections, including a rare brain infection (PML).
- Gut problems and low blood counts are common and can limit the dose.
- No human study has looked at lifespan, healthy years or anything else about ageing.
What this does not tell you: This drug exists to damp down the immune system, and its harms follow from that. The lifespan result tells you it does not make mice live longer. It does not rule out that some narrower immune approach might. Nothing here supports any ageing use. The cancer and infection warnings make trying it truly dangerous.
The state of the research
The value of this failure is what it rules out, not what it shows. Rapamycin makes mice live longer more reliably than any other drug, and it damps down the immune system. So the idea that a quieter immune system is the reason has to be checked. Testing a strong immune-damping drug that works a totally different way is the right check. The answer was no longer life.
That makes the mTOR explanation for rapamycin more likely, by ruling out the other one. It rests on one failed test in one program, so it narrows the question more than it settles it.
The National Institute on Aging runs the Interventions Testing Program at three separate labs: The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a mixed breed made by crossing four strains, so a result cannot be a quirk of one strain. Compounds go in the food. Both sexes are tested. Each group is big enough to spot about a 10 percent change in lifespan. Results are checked with one test for typical lifespan and another for the longest-lived mice. The failures are published next to the wins. No other ageing research has all of that together. That is why a no from this program means much more than a no from one lab.
The evidence, in charts
Fig. 1a · how many people
227people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ALMS, The New England Journal of Medicine 2011 | 227 | 100% |
The whole total is one study of 227. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Animal study · done in animals133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2004 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 320.3 Da for mycophenolic acid. A small molecule, not a peptide.
- Half-life
- About 17 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: Roughly 16 to 18 hours for mycophenolic acid after administration as mycophenolate mofetil, with enterohepatic recirculation producing a secondary peak.
No amino acid sequence is on file for Mycophenolic acid, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2011Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
For keeping lupus kidney disease in remission, mycophenolate held up better than the older drug azathioprine over three years. 227 people took part. About half as many people on it had their treatment fail. Side effects were common on both, and fewer people stopped mycophenolate because of them.
227 patients with lupus nephritis who had responded to induction, randomised double-blind to mycophenolate mofetil 2 g daily or azathioprine 2 mg/kg daily for 36 months (ALMS maintenance). Treatment failure in 16.4% versus 32.4% (HR 0.44, 95% CI 0.25 to 0.77, p=0.003). Serious adverse events 23.5% versus 33.3%; withdrawal for adverse events 25.2% versus 39.6% (p=0.02).
- Study in people2004Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.
Two forms of the same active drug were compared in 423 people after a kidney transplant. Both groups also took cyclosporine and steroids. The coated sodium form prevented rejection as well as the older form over a year. Gut side effects were similar.
423 new kidney transplant recipients randomised double-blind to enteric-coated mycophenolate sodium 720 mg or mycophenolate mofetil 1,000 mg twice daily, with cyclosporine and corticosteroids, for 12 months. Efficacy failure at 6 months 25.8% versus 26.2%, meeting therapeutic equivalence. Biopsy-proven acute rejection at 12 months 22.5% versus 24.3%; dose changes for gastrointestinal events 15.0% versus 19.5%.
- Animal study2024Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not
In mice. In the NIA mouse lifespan program, mycophenolic acid did not clearly make either sex live longer at the dose and method used.
Interventions Testing Program. Mycophenolic acid did not increase lifespan significantly at the dose and method of administration tested, in either sex.
Common questions
Has Mycophenolic acid been tested in people?
Yes. 227 people given it across 2 completed trials cited here, 0 of which found nothing. Mycophenolic acid is a transplant drug that damps down the immune system. It was tested on the idea that rapamycin might help mice live longer by damping down the immune system too. It did not extend mouse lifespan in either sex. That points to rapamycin working some other way.
What is the Mycophenolic acid dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved as mycophenolate mofetil and mycophenolate sodium to stop the body rejecting a transplanted organ. It carries boxed warnings, the FDA's strongest, for harm to an unborn baby, cancer and serious infection. No ageing use.
Is Mycophenolic acid FDA-approved?
FDA-approved as mycophenolate mofetil and mycophenolate sodium to stop the body rejecting a transplanted organ. It carries boxed warnings, the FDA's strongest, for harm to an unborn baby, cancer and serious infection. No ageing use.
Does suppressing the immune system extend lifespan?
Not on this evidence. A strong immune-damping drug that works nowhere near mTOR did not make mice of either sex live longer. That makes a quieter immune system a less likely reason for rapamycin's effect, and leaves blocking mTOR as the better bet.
Could I take this for longevity?
No, and this is one of the strongest no answers here. It carries the FDA's strongest warnings for harm to unborn babies, cancer and serious infection. There is no ageing benefit at all on the other side of the scale.
Why test a transplant drug for ageing?
To separate two possible reasons for rapamycin's effect. If damping down the immune system were doing the work, an unrelated immune-damping drug should have shown something. It did not. That is how a well-chosen failed test moves a field forward.